Swedish Evaluation of Left Ventricular Assist Device as Permanent Treatment in End-stage Heart Failure

End-stage Heart Failure Clinical Trial

— SweVAD  

Official title:

Swedish Evaluation of Left Ventricular Assist Device

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02592499
• Other study ID #: ver 6.0
• Secondary ID: 635-14
• Status: Recruiting
• Phase: N/A
• Start date: June 2016
• Est. completion date: December 2025

Study information

• Verified date: April 2023
• Source: Vastra Gotaland Region
• Contact: Göran Dellgren, MD
• Phone: +4631-342 88 63
• Email: goran.dellgren[@]vgregion.se
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is a prospective, randomized, non-blinded, national, multi-center study. The study will consist of the assignment of eligible patients to treatment with either a HeartMate III (HM III) left ventricular assist device system or to pharmacological treatment (optimal medical management, OMM) according to current guidelines. Eighty (80) patients will be enrolled in this study and randomized in a 1:1 fashion between the HM III and OMM, based on a modified power calculation.

Description:

The primary objective is to compare survival between left Ventricular Assist Device (LVAD) destination therapy and optimal medical management in a Swedish end stage heart failure population ineligible for cardiac transplantation. The secondary objective is to compare treatment groups with respect to organ function, functional capacity, quality of life and adverse events. All patients enrolled in the study will be followed through 2 years. Patients who continue to be on going with the HM III or on OMM past 2 years will continue be followed for their outcomes and adverse events for up to 5 years. Patient recruitment was expected to occur over 24 months, but due to difficulties in recruiting patients will be longer (approximately 48 months) The study will be conducted in Sweden at all 7 University Hospitals and implantations will be performed in 5 sites.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: December 2025
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed informed consent

2. Adult (= 18 years)

3. Chronic heart failure = 45 days or stable not supported by mechanical circulatory support since >7days on single inotrope.

4. Left ventricular ejection fraction = 30%.

5. NYHA IIIB-IV, INTERMACS profile 2-6

6. At least 2 of 4 adverse prognostic criteria:

• SHFM estimated 1-year survival =75%
• NTproBNP = 2000 ng/l
• VO2 max < 14 ml/kg/min or <50% of predicted VO2max with attainment of anaerobic threshold (AT), or unable to perform.
• Need for continuous or intermittent inotropic support or >2 hospitalizations during last 6 months.

7. Receiving medical management with optimal doses of betablockers, ACE-inhibitors or ARBs, and MRAs for at least 30 days if tolerated.

8. Receiving CRT if indicated for at least 45 days.

9. Receiving ICD if indicated and appropriate.

10. Ineligible for cardiac transplantation (e.g. high age and/or co-morbidities)

11. Considered suitable for the study by a multidisciplinary board

Exclusion Criteria:

1. Eligible for heart transplantation or is likely to become eligible after VAD treatment (bridge-to-candidacy)

2. Indication for revascularisation, valvular surgery or other cardiac intervention expected to improve cardiac function and prognosis (CABG, PCI TAVI, mitraclip etc.)

3. INTERMACS profile 1 "crash and burn"

4. On-going mechanical circulatory support.

5. Heart failure due to restrictive cardiomyopathy pericardial disease, active myocarditis or uncorrected thyroid disease.

6. Mechanical aortic valve that will not be converted to a bioprosthesis or patch

7. Moderate to severe aortic insufficiency without plans for correction

8. Technical obstacles, which pose an inordinately high surgical risk

9. Active, uncontrolled infection

11. Stroke within 90 days or carotid artery stenosis > 80 % 12. Significant vascular disease. 13. Severe COPD or severe restrictive lung disease. 14. Intrinsic hepatic disease as defined by liver enzyme values (AST or ALT or total bilirubin) > 5 times the upper limit of normal, or INR > 2.0, which is not due to anti-coagulant therapy.

15. Intolerance to anticoagulant or antiplatelet therapies or any other operative therapy the patient will require based upon the patient's health status.

16. Platelet count < 50,000. 17. Measured GFR <20 ml/min/1.73m2 unresponsive to inotrope treatment or chronic dialysis.

18. High risk for right ventricular failure according to echocardiography and/or invasive hemodynamic measurements as judged by the investigator (>2 parameter constitute an exclusion criteria) using a combination of the: a. Severe TI b. TAPSE < 0.72 cm c. RVEDD/LVEDD > 0.72 d. CVP > 16 mm Hg e. MPAP - RAP < 10 mmHg SPAP-DPAP/CVPm >1 ok, <0.5 very bad, in between borderline f. CVP/PCWP > 0.63 g. RVSWI < 300 mm Hg x ml/m2 h. Bilirubin > 34 micromol/L 19. Body Mass Index (BMI) > 42 kg/m2. 20. Psychiatric disease, cognitive dysfunction, alcohol or drug abuse, or psychosocial issues that are likely to impair study compliance 21. Female of childbearing age with a positive pregnancy test or not willing to use adequate contraceptive precautions during the study.

22. Condition, other than heart failure, that could limit survival to less than 2 years.

Related Conditions & MeSH terms

• End-stage Heart Failure
• Heart Failure

Intervention

Device:
• HM III

Other:
• OMM, optimal medical management
Patients randomized to OMM will be treated according to international guidelines. All patients should receive a beta blocker, an ACE-inhibitor or an Angiotension II receptor blocker, and a mineralocorticoid receptor antagonist if tolerated and at optimally titrated doses according to guidelines. Loop diuretics should also be used as needed to control fluid retention. Other drugs that may relieve symptoms and improve prognosis can be used (incl ivabradin, digoxin, hydralazine,isosorbiddinitrate, anticoagulant agents). Patients that have an indication for implantable cardioverter defibrillator (ICD) and/or cardiac resynchronization therapy (CRT) should receive such therapy. Surgical interventions that may be indicated for specific underlying or contributing causes of heart failure.

Locations

Country	Name	City	State
Sweden	Sahlgrenska Univesitetssjukhustet, Transplantationscentrum	Gothenburg
Sweden	Linköping Univ Hospital	Linköping
Sweden	Skåne University Hospital	Lund
Sweden	Örebro Univ Hospital	Örebro
Sweden	Karolinska Univ Hospital	Stockholm
Sweden	Univ Hospital of Umeå	Umeå
Sweden	Uppsala Univ Hospital	Uppsala

Sponsors (7)

Lead Sponsor	Collaborator
Vastra Gotaland Region	Karolinska University Hospital, Region Örebro County, Skane University Hospital, University Hospital, Linkoeping, University Hospital, Umeå, Uppsala University Hospital

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival at two years of follow-up	survival	2 years,
Secondary	Number of participants free from disabling stroke during the 2-year follow-up period	Survival free from disabling stroke (Modified Rankin Scale (MRS) >3)	2 years
Secondary	A composite endpoint of "survival free from disabling stroke", survival and non-planned hospitalizations	Survival free from a composite endpoint of disabling stroke, survival and non-planned hospitalizations	2 years
Secondary	Survival at year of follow-up	Survival at year	1 year
Secondary	Functional capacity (NYHA) during the 2-year follow-up period	functional capacity determined by NYHA classification	2 years
Secondary	Functional capacity (6 min walk-test) during the 2-year follow-up period	functional capacity determined by 6 min walk-test	2 years
Secondary	Functional capacity (peak VO2)	functional capacity determined by peak VO2	2 years
Secondary	Health-related quality of Life during the 2-year follow-up period	Health-related quality of Life asses with EQ-5D-5L, SF-36 and KCCQ	2 years
Secondary	Number of participants with heart-failure related events		2 years
Secondary	Cost-effectiveness during the 2-year follow-up period	Cost effectiveness calculated with QUALY (Quality-adjusted Life-year) and LY (Life year)	2 years
Secondary	Renal function during the 2-year follow-up period	Glomerular filtration rate evaluated by 51 chrome-EDTA or Iohexol clearance	2 years
Secondary	Hospital admissions during the 2-year follow-up period	Number of hospital admissions	2 years
Secondary	Number of participants with serious adverse events (SAEs)		2 years
Secondary	Functional capacity (peak VO2)	functional capacity determined by peak VO2	1 year
Secondary	Three-years survival	survival	3 years
Secondary	Four-years survival	survival	4 years
Secondary	Five-years survival	survival	5 years